Étrasimode
Étrasimode (1206123-37-6):
Etrasimod is a novel oral, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of adult patients with moderately to severely active ulcerative colitis. It can partially reversibly block the outflow of lymphocytes and reduce the number of lymphocytes in the peripheral blood, thereby reducing the migration of lymphocytes into the intestine and exerting a therapeutic effect. Product Name: Etrasimod CAS No.: 1206123-37-6 Assay: 99% Specification: CP, EP,
Éthyl2-(7-hydroxy-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétate (1206124-13-1)
Ethyl2-(7-hydroxy-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate is an intermediate of Etrasimod. Product Name: Ethyl2-(7-hydroxy-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate CAS No.: 1206124-13-1 Assay: 98% End Use: Etrasimod Molecular Formula: C15H17NO3 Molecular Weight: 259.3 Shelf Life: 2 Years Package: 25kg/drum
4-ChloroMéthyl-1-cyclopentyl-2-trifluoroMéthyl-benzène (957208-65-0)
4-ChloroMethyl-1-cyclopentyl-2-trifluoroMethyl-benzene is an intermediate of Etrasimod. Product Name: 4-ChloroMethyl-1-cyclopentyl-2-trifluoroMethyl-benzene CAS No.: 957208-65-0 Assay: 98% End Use: Etrasimod Molecular Formula: C13H14ClF3 Molecular Weight: 262.7 Shelf Life: 2 Years Package: 25kg/drum
